Cardiovascular calcification progression - A comparison of sevelamer and calcium-based phosphate binders

Blood Purification

Volumn 23, Issue SUPPL. 1, 2005, Pages 20-23

  Raggi, Paolo ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; COLECALCIFEROL; PHOSPHATE BINDING AGENT; SERTUERNER; SEVELAMER; EPOXIDE; PHOSPHATE; POLYAMINE; POLYETHYLENE DERIVATIVE;

AORTA VALVE; ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; CALCIFICATION; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; EDITORIAL; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MINERAL METABOLISM; MITRAL VALVE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; CALCINOSIS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; METABOLISM; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

CALCINOSIS; CALCIUM; CARDIOVASCULAR DISEASES; EPOXY COMPOUNDS; HUMANS; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDIES; PHOSPHATES; POLYAMINES; POLYETHYLENES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 20844432216     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083714     Document Type: Editorial

References (22)

1. US Renal Data System: USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004.
2. Longenecker JC, Coresh J, Powe NR, et al: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 2002;13:1918-1927.
3. Block G, Hulbert-Shearon T, Levin N, et al: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998;31:607-617.
4. Guerin AP, London GM, Marchais SJ, et al: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-1021.
5. Blacher J, Guerin AP, Pannier B, et al: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942.
6. Raggi P, Boulay A, Chasan-Taber S, et al: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
7. London GM, Guerin AP, Marchais SJ, et al: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740.
8. London GM: Cardiovascular calcifications in uremic patients: Clinical impact on cardiovascular function. J Am Soc Nephrol 2003;14:S305-S309.
9. Block GA, Klassen PS, Lazarus JM, et al: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
10. Goodman WG, Goldin J, Kuizon BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
11. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
12. Agatston AS, Janowitz WR, Hildner FJ, et al: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-832.
13. Chertow GM, Raggi P, McCarthy JT, et al: The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-314.
14. Braun J, Asmus HG, Holzer H, et al: Long-term comparison of a calcium-free phosphate binder and calcium carbonate - phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004;62:104-115.
15. Raggi P, Bommer J, Chertow GM: Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004;13:134-141.
16. Reynolds JL, Joannides AJ, Skepper JN, et al: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004;15:2857-2867.
17. Yang H, Curinga G, Giachelli CM: Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004;66:2293-2299.
18. Braun J, Oldendorf M, Moshage W, et al: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996;27:394-401.
19. Chertow GM, Raggi P, Chasan-Taber S, et al: Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-1496.
20. Hsu CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997;29:641-649.
21. Speer MY, Giachelli CM: Regulation of cardiovascular calcification. Cardiovasc Pathol 2004;13:63-70.
22. Raggi P, James G, Burke S, Bommer J, Taber SC, Holzer H, Braun J, Chertow G: Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005 (in press).